
Please try another search
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Shami J. Patel | 55 | 2024 | Director |
Brian G. Atwood | 72 | 2024 | Director |
Kathleen D. LaPorte | 63 | 2024 | Independent Director |
Christopher B. Ehrlich | 55 | 2024 | CEO & Chair |
Michael Byrnes | 48 | 2024 | Independent Director |
Lindsey Rolfe | 57 | 2024 | Independent Director |
Lawrence Corey | 78 | - | Co-founder & Head of Scientific Advisory Board |
Antonio Lanzavecchia | - | - | Scientific Advisor |
Rafi Ahmed | - | - | Scientific Advisor |
Adrian Bot | - | - | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review